Insulet Corp. logo
PODDInsulet Corp.

Total Return:-52.14%(TTM)

Over the latest trailing 12-month period, total return cagr is -52.14%. The comparable SPY value is +22.18%. Year-to-date total return is -47.62%. Total return includes price appreciation and reinvested dividends.

Growth of $10,000 in PODD

$93,283

(9.3x return)

Invested on May 15, 2007

Growth of $10,000 in SPY (S&P 500)

$68,554

(6.9x return)

Invested on May 15, 2007

Hypothetical Growth of $10,000

This chart illustrates the cumulative performance of a hypothetical $10,000 investment. It assumes that all dividends paid by both the stock and SPY are reinvested in additional shares on the payment date, showing the true long-term compounding impact of distributions.

Recent Performance Indicators

YTD Total Return

-47.6%

1-Year Total Return

-52.1%

Current Dividend Yield

0.00%

Price CAGR vs. Total Return CAGR

Compound Annual Growth Rate (CAGR) is shown below. The difference between price CAGR and total return CAGR is the compound contribution of dividends reinvested.

Holding PeriodPrice CAGRTotal Return CAGRDividend Addition
1 Year(52.1%)(52.1%)
3 Years(19.7%)(19.7%)
5 Years(11.7%)(11.7%)
10 Years+18.0%+18.0%
15 Years+14.1%+14.1%
20 Years

About Insulet Corp.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Acton, MA
5,400 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Ashley A. McEvoy